Skip to main content
Top
Published in: Diabetologia 12/2017

01-12-2017 | Commentary

Osteomyelitis of the foot: non-surgical management, SPECT/CT scanning and minimising the duration of antibiotic use

Author: William J. Jeffcoate

Published in: Diabetologia | Issue 12/2017

Login to get access

Abstract

In a paper in this issue of Diabetologia (DOI: https://​doi.​org/​10.​1007/​s00125-017-4417-x), Vouillarmet and colleagues have explored the use of single-photon emission computed tomography (SPECT)/computed tomography (CT) to define remission during non-surgical management of osteomyelitis of the foot. Their experience in a non-controlled observational study of 45 individuals was that a negative white blood cell-SPECT/CT scan is a reliable marker of remission, while a positive scan at the end of antibiotic treatment may be relatively useful in the prediction of future short- to medium-term relapse. These findings and conclusions are discussed in the light of current uncertainties relating to the diagnosis of bone infection and the lack of any tested measure that can be used to indicate either its presence or its persistence. In this respect, it is concluded that the value of this approach, and in which population, remains to be clearly established.
Literature
2.
go back to reference Berendt AR, Peters EJ, Bakker K et al (2008) Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 24(Suppl1):S145–S161CrossRefPubMed Berendt AR, Peters EJ, Bakker K et al (2008) Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev 24(Suppl1):S145–S161CrossRefPubMed
3.
go back to reference Lipsky BA, Aragon-Sanchez J, Diggle M et al (2016) IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev 32(Suppl1):45–74CrossRefPubMed Lipsky BA, Aragon-Sanchez J, Diggle M et al (2016) IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev 32(Suppl1):45–74CrossRefPubMed
4.
go back to reference La Fontaine J, Bhavan K, Lam K et al (2016) Comparison between Tc-99m WBC SPECT/CT and MRI for the diagnosis of biopsy-proven diabetic foot osteomyelitis. Wounds 28:271–278PubMed La Fontaine J, Bhavan K, Lam K et al (2016) Comparison between Tc-99m WBC SPECT/CT and MRI for the diagnosis of biopsy-proven diabetic foot osteomyelitis. Wounds 28:271–278PubMed
5.
go back to reference Aslangul E, M’bemba J, Caillat-Vigneron N et al (2013) Diagnosing soft tissue osteomyelitis in patients without signs of soft tissue infection by coupling hybrid 67Ga SPECT/CT with bedside percutaneous bone puncture. Diabetes Care 36:2203–2210CrossRefPubMedPubMedCentral Aslangul E, M’bemba J, Caillat-Vigneron N et al (2013) Diagnosing soft tissue osteomyelitis in patients without signs of soft tissue infection by coupling hybrid 67Ga SPECT/CT with bedside percutaneous bone puncture. Diabetes Care 36:2203–2210CrossRefPubMedPubMedCentral
6.
go back to reference Vouillarmet J, Morelec I, Thivolet C (2014) Assessing diabetic foot osteomyelitis remission with white blood cell SPECT/CT imaging. Diabet Med 31:1093–1099CrossRefPubMed Vouillarmet J, Morelec I, Thivolet C (2014) Assessing diabetic foot osteomyelitis remission with white blood cell SPECT/CT imaging. Diabet Med 31:1093–1099CrossRefPubMed
7.
go back to reference Lazaga F, Van Asten SA, Nichols A et al (2016) Hybrid imaging with 99mTc-WBC SPECT/CT to monitor the effect of therapy in diabetic foot osteomyelitis. Int Wound J 13:1158–1160CrossRefPubMed Lazaga F, Van Asten SA, Nichols A et al (2016) Hybrid imaging with 99mTc-WBC SPECT/CT to monitor the effect of therapy in diabetic foot osteomyelitis. Int Wound J 13:1158–1160CrossRefPubMed
8.
go back to reference van Asten SA, Jupiter DC, Mithani M, La Fontaine J, David KE, Lavery LA (2017) Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis. Int Wound J 14:142–148CrossRefPubMed van Asten SA, Jupiter DC, Mithani M, La Fontaine J, David KE, Lavery LA (2017) Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis. Int Wound J 14:142–148CrossRefPubMed
9.
go back to reference Van Asten SA, Nichols A, La Fontaine J, Bhavan K, Peters EJ, Lavery LA (2017) The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis. Int Wound J 14:40–45CrossRefPubMed Van Asten SA, Nichols A, La Fontaine J, Bhavan K, Peters EJ, Lavery LA (2017) The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis. Int Wound J 14:40–45CrossRefPubMed
10.
go back to reference Game FL, Jeffcoate WJ (2008) Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia 51:962–967CrossRefPubMed Game FL, Jeffcoate WJ (2008) Primarily non-surgical management of osteomyelitis of the foot in diabetes. Diabetologia 51:962–967CrossRefPubMed
11.
go back to reference Tone A, Nguyen S, Devemy F et al (2015) Six-week versus twelve week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 38:302–307CrossRefPubMed Tone A, Nguyen S, Devemy F et al (2015) Six-week versus twelve week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care 38:302–307CrossRefPubMed
Metadata
Title
Osteomyelitis of the foot: non-surgical management, SPECT/CT scanning and minimising the duration of antibiotic use
Author
William J. Jeffcoate
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 12/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4429-6

Other articles of this Issue 12/2017

Diabetologia 12/2017 Go to the issue

Up Front

Up Front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.